Patients with open-angle glaucoma who received argon laser trabeculoplasty plus topical betaxolol halved their progression risk, compared to control patients who received no immediate treatment, study results show. Magnitude of the initial intraocular pressure (IOP) reduction represented a major influence on outcome, researchers add.
The researchers, from Stony Brook University School of Medicine, New York and other centres in the United States and Sweden, participated in the Early Manifest Glaucoma Trial (EMGT). They treated 129 patients with laser trabeculoplasty plus betaxolol, while 126 patients acted as untreated controls. The patients were followed-up every 3 months. Fifty-three percent progressed over 6 years follow up.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!